1,344 reports of this reaction
3.7% of all INTERFERON BETA 1B reports
#2 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #2 most commonly reported adverse reaction for INTERFERON BETA 1B, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 1,344 FDA adverse event reports linking INTERFERON BETA 1B to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 3.7% of all 36,175 adverse event reports for this drug.
Patients taking INTERFERON BETA 1B who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among INTERFERON BETA 1B users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for INTERFERON BETA 1B:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 1,344 FDA reports for INTERFERON BETA 1B. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 3.7% of all adverse event reports for INTERFERON BETA 1B, making it one of the most commonly reported side effect.
If you experience multiple sclerosis relapse while taking INTERFERON BETA 1B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.